Optimization of checkpoint immunotherapy against lung cancer
Trials underway
Optimization of checkpoint immunotherapy against lung cancer
Investigators at the University of Minnesota are completing a phase II, double blind, placebo controlled clinical trial in which patients receive either microbiota therapy or placebo alongside immunotherapy for non-small cell lung cancer. The clinical trial is underway with additional details available here.
Achieving Cures Together is tax exempt pursuant to IRC Section 501(c)(3). Contributions are deductible to the extent allowed by law.
